Chemical Namecaplacizumab-yhdp
Dosage FormInjectable (intravenous, subcutaneous; 11 mg/vial)
Drug ClassMonoclonal antibodies
CompanyAblynx Nv
Approval Year2019


  • Cablivi is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cablivi (caplacizumab-yhdp) Prescribing Information2019Sanofi
Document TitleYearSource
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. 2020The International Society on Thrombosis and Haemostasis